On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day
Feb 27, 2017 12:01 pm UTC| Business
LEIDEN, the Netherlands, Feb. 27, 2017 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare...
Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
Feb 27, 2017 12:01 pm UTC| Business
WALTHAM, Mass., Feb. 27, 2017 -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced its...
Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
Feb 27, 2017 12:01 pm UTC| Business
WALTHAM, Mass., Feb. 27, 2017 -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced its...
Antares Pharma Announces FDA Acceptance of New Drug Application for Quickshot® Testosterone
Feb 27, 2017 12:01 pm UTC| Business
EWING, N.J., Feb. 27, 2017 -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that the New Drug Application (NDA) for QuickShot® Testosterone (QST), a drug-device combination product for the delivery of testosterone...
Antares Pharma Announces FDA Acceptance of New Drug Application for Quickshot® Testosterone
Feb 27, 2017 12:01 pm UTC| Business
EWING, N.J., Feb. 27, 2017 -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that the New Drug Application (NDA) for QuickShot® Testosterone (QST), a drug-device combination product for the delivery of testosterone...
Feb 27, 2017 12:01 pm UTC| Business
PLYMOUTH MEETING, Pa., Feb. 27, 2017 -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its SynCon® WT1 cancer immunotherapy was capable of breaking immune tolerance and inducing neo-antigen-like T cell...
Feb 27, 2017 12:01 pm UTC| Business
PLYMOUTH MEETING, Pa., Feb. 27, 2017 -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its SynCon® WT1 cancer immunotherapy was capable of breaking immune tolerance and inducing neo-antigen-like T cell...